Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Karine Egan"'
Publikováno v:
PLoS Medicine, Vol 4, Iss 5, p e157 (2007)
BackgroundSuppression of prostacyclin (PGI2) is implicated in the cardiovascular hazard from inhibitors of cyclooxygenase (COX)-2. Furthermore, estrogen confers atheroprotection via COX-2-dependent PGI2 in mice, raising the possibility that COX inhib
Externí odkaz:
https://doaj.org/article/e2744e61fc8c4edd98d74d44fa150e40
Autor:
Jennifer S. Goldsby, Kenneth K. Wu, Karine Egan, Garret A. FitzGerald, Wan-Song A. Wun, Jaou-Chen Huang
Publikováno v:
Human Reproduction. 22:2851-2856
Background Prostacyclin (PGI(2)) plays an important role in mouse embryo development and implantation. However, it is unclear whether its action is mediated via the I prostaglandin receptor (IP). Methods We compared the preimplantation development of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28e58e2764dc98c00551b9123608960b
https://doi.org/10.1093/humrep/dem304
https://doi.org/10.1093/humrep/dem304
Autor:
John A. Lawson, Susanne Fries, Garret A. FitzGerald, Daniel J. Rader, Emer M. Smyth, Karine Egan, Beverly H. Koller
Publikováno v:
Science. 306:1954-1957
Female gender affords relative protection from cardiovascular disease until the menopause. We report that estrogen acts on estrogen receptor subtype alpha to up-regulate the production of atheroprotective prostacyclin, PGI 2 , by activation of cycloo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1145b54cb3dac51006d7f5fc5f42ac36
https://doi.org/10.1126/science.1103333
https://doi.org/10.1126/science.1103333
Autor:
Weisong Zhou, Koichi Hashimoto, Peter F. Wright, R. Stokes Peebles, Jamye F. O'Neal, Robert D. Collins, Jason D. Morrow, Karine Egan, Kasia Goleniewska, Tatsuo Suzutani, Mark W. Geraci, Barney S. Graham, Russell K. Durbin, Garret A. FitzGerald
Publikováno v:
Journal of Virology. 78:10303-10309
The role of prostanoids in modulating respiratory syncytial virus (RSV) infection is unknown. We found that RSV infection in mice increases production of prostaglandin I 2 (PGI 2 ). Mice that overexpress PGI 2 synthase selectively in bronchial epithe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed7ecae3c656fcf6f60b5d416c0bc04
https://doi.org/10.1128/jvi.78.19.10303-10309.2004
https://doi.org/10.1128/jvi.78.19.10303-10309.2004
Publikováno v:
Thrombosis Research. 110:311-315
Deletion of membrane receptors for prostaglandins has revealed their importance in diverse biological systems. Some evidence has accrued to support the contention that they may also ligate nuclear receptors, particularly peroxisomal proliferator acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b128796ef36c8d14c078174775ca8df0
https://doi.org/10.1016/s0049-3848(03)00418-3
https://doi.org/10.1016/s0049-3848(03)00418-3
Autor:
Weisong Zhou, Koichi Hashimoto, Garret A. FitzGerald, Karine Egan, Timothy S. Blackwell, Shaoquan Ji, Jamye F. O'Neal, R. Stokes Peebles, Kasia Goleniewska, Mark W. Geraci
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 178(2)
Signaling through the PGI2 receptor (IP) has been shown to inhibit inflammatory responses in mouse models of respiratory syncytial viral infection and OVA-induced allergic responses. However, little is known about the cell types that mediate the anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd48cb5e7e560475a6083b6d7b045720
https://pubmed.ncbi.nlm.nih.gov/17202330
https://pubmed.ncbi.nlm.nih.gov/17202330
Autor:
Béatrice Desvergne, Karine Egan, David Bishop-Bailey, Timothy D. Warner, Jane Mitchell, Walter Wahli, Garret A. FitzGerald, Ferhana Y. Ali
Publikováno v:
American journal of respiratory cell and molecular biology. 34(2)
Prostacyclin and its mimetics are used therapeutically for the treatment of pulmonary hypertension. These drugs act via cell surface prostacyclin receptors (IP receptors); however, some of them can also activate the nuclear receptor peroxisome prolif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c05eeca037f5fef867349e546f6a422a
https://pubmed.ncbi.nlm.nih.gov/16239641
https://pubmed.ncbi.nlm.nih.gov/16239641
Autor:
John A. Lawson, Emer M. Smyth, Beverley Koller, Garret A. FitzGerald, Susanne Fries, Daniel J. Rader, Karine Egan
Publikováno v:
Obstetrical & Gynecological Survey. 60:309-310
Before menopause, women are relatively protected against cardiovascular disease. Although estrogen (E 2 ) retards atherogenesis in animal models and improves endothelial function in women with hyperlipidemia, the mechanisms of atheroprotection remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffaa82893cb4d02ed589971ec0230e9b
https://doi.org/10.1097/01.ogx.0000160574.33752.4f
https://doi.org/10.1097/01.ogx.0000160574.33752.4f
Autor:
Philipp le Coutre, Cliona McDowell, Eibhlin Conneally, Michael O'Dwyer, Mary Frances McMullin, Karine Egan, Stephen E. Langabeer, Brian Moulton, Ronan T. Swords, Arnon Nagler, Francis J. Giles, Marzena Wieczorkowska
Publikováno v:
Blood. 118:3774-3774
Abstract 3774 BACKGROUND/METHODS: Data from the ENESTnd phase III trial showed superiority of nilotinib over imatinib leading to accelerated approval of nilotinib as initial treatment of ECPCML at a dose of 300mg BID. ICORG, the All-Ireland Cooperati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5398b71a36415df9500ab163eb0fea32
https://doi.org/10.1182/blood.v118.21.3774.3774
https://doi.org/10.1182/blood.v118.21.3774.3774
Autor:
Mary Frances McMullin, Cliona McDowell, Ronan T. Swords, Michael O'Dwyer, Brian Moulton, Philipp le Coutre, Eibhlin Conneally, Francis J. Giles, Stephen E. Langabeer, Karine Egan, Marzena Wieczorkowska
Publikováno v:
Blood. 116:3427-3427
Abstract 3427 Recently, early results of the ENESTnd phase III trial showing superiority of nilotinib over imatinib, led to accelerated approval of Nilotinib as initial treatment of ECP CML at a dose of 300mg BID. Independently, since December 2008,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1593789d81707778ebfa1075de401b8
https://doi.org/10.1182/blood.v116.21.3427.3427
https://doi.org/10.1182/blood.v116.21.3427.3427